Not convinced - need more specifics.
I think the market cap is already demanding and now has to absorb a whole lot of more shares.
Expenses are now big at 4m+ - June cash would be gone by now at that rate
View in Vivo is vague at best in its market presence.
No idea whether regulatory submissions have been made for neurosurgery.
I am convinced the technology will prevail as an intra-operative in vivo pathology tool, it just makes too much sense but the above is looking brittle to me.
1.3 Million in Revenue !!!, page-2
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OIL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.5¢ |
Change
-0.005(3.13%) |
Mkt cap ! $129.4M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.0¢ | 15.0¢ | $25.24K | 161.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 25102 | 15.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 70000 | 1 |
View Market Depth
| Last trade - 13.14pm 03/12/2024 (20 minute delay) ? |
| OIL (ASX) Chart |
